Kura Oncology(KURA) - 2025 Q4 - Annual Report

FDA Approval and Market Opportunity - The FDA approved KOMZIFTI (ziftomenib) on November 13, 2025, for treating adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation[22]. - The initial U.S. market opportunity for relapsed or refractory NPM1-mutated AML treatment is estimated at approximately $350.0 to $400.0 million annually, with a total annual market opportunity across relapsed or refractory and frontline AML estimated at approximately $7.0 billion[50]. - KOMZIFTI is the first and only menin inhibitor approved by the FDA for once-daily oral administration, enhancing patient compliance[45]. Clinical Trial Results - The complete remission (CR) rate plus CR with partial hematologic recovery (CRh) in the KOMET-001 trial was 21.4%, with a median duration of CR+CRh of five months[41]. - 88% of patients who achieved CR or CRh did so within six months of initiating KOMZIFTI[41]. - Among 51 patients with relapsed or refractory NPM1-mutated AML, the objective response rate was 65%, with a median overall survival of 54.9 weeks[71]. - The combination of ziftomenib with 7+3 chemotherapy demonstrated a 93% complete response rate in NPM1-mutated AML patients in the KOMET-007 trial[66]. - In the Phase 1 KOMET-007 trial, ziftomenib combined with venetoclax and azacitidine showed a 73% complete response rate in newly diagnosed NPM1-mutated AML patients[63]. Safety and Efficacy - The safety profile of KOMZIFTI was manageable, with most adverse events being Grade 1 or Grade 2, and no Grade 4 or Grade 5 QTc interval prolongation reported[42]. - Ziftomenib is expected to address up to 50% of AML cases, including those with NPM1 mutations and KMT2A rearrangements[58]. Development and Future Plans - The company plans to establish KOMZIFTI as the leading menin inhibitor in relapsed or refractory NPM1-mutated AML, aiming for majority class share[30]. - The clinical development program includes two registrational Phase 3 trials of ziftomenib in combination with chemotherapy for newly diagnosed AML[23]. - The company anticipates topline results from the MRD-negative complete response accelerated endpoint in the intensive chemotherapy setting by 2028[65]. - The company plans to advance its first next-generation menin inhibitor, KO-7246, into IND-enabling studies in diabetes and cardiometabolic diseases in 2026[92]. Competitive Landscape and Market Access - The company faces substantial competition from major pharmaceutical and biotechnology companies, which may impact the development and commercialization of its products[122]. - At least 80% of private payors have established coverage policies for KOMZIFTI, with some requiring patients to use KOMZIFTI before other menin inhibitors[49]. - The market access team has engaged with 100% of targeted payor organizations responsible for coverage decisions affecting over 90% of insured lives prior to the launch of KOMZIFTI[131]. Regulatory and Compliance - The FDA approval process involves extensive regulation, including preclinical tests and clinical trials to establish safety and effectiveness[155]. - The FDA may require post-approval Phase 4 testing to confirm clinical benefits, with failure to conduct these trials potentially leading to market withdrawal[175]. - Compliance with various healthcare regulations is essential, as violations can lead to significant penalties and operational restrictions[206]. Financial and Corporate Structure - The company is eligible to receive up to $1.491 billion in total upfront and milestone payments under the Kyowa License Agreement, including $330 million for the expanded Field[118]. - As of December 31, 2025, the company has received or expects to receive a total of $592.6 million in upfront, milestone, and profit-sharing payments under the Kyowa License Agreement[118]. - The company has hired a field sales team with an average of over 20 years of industry experience to drive adoption of KOMZIFTI, targeting over 4,000 accounts[130]. Employee and Corporate Culture - As of December 31, 2025, the company employed 260 full-time employees, split evenly between research and development and administrative roles[216]. - The company invests in employee development through competitive compensation and wellness initiatives, overseen by senior management[217]. - The Code of Business Conduct and Ethics is implemented to ensure core values are upheld across operations, with annual training for all staff[218].